Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 12/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 12/20 | 0.55 |
| ▸ | CACNB1 | Q02641 | 12/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 12/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563484 | 0.93 | CACNA2D1 (0.57) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL2793083 | 0.86 | HSD11B1 (0.46) | CACNA2D1CACNA1BCACNB1CACNA1CHSD11B1 | |
| SCHEMBL8268615 | 0.84 | CACNA2D1 (0.71) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL2794491 | 0.84 | GRM7 (0.47) | HSD11B1MEN1KMT2A | |
| SCHEMBL4278746 | 0.82 | HSD11B1 (0.46) | CACNA2D1CACNA1BCACNB1CACNA1CHSD11B1 | |
| SCHEMBL2794432 | 0.82 | CACNA2D1 (0.46) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL18390864 | 0.82 | HSD11B1 (0.73) | HSD11B1MEN1KMT2A | |
| SCHEMBL2797056 | 0.80 | CACNA2D1 (0.53) | CACNA2D1CACNA1BCACNB1CACNA1CHSD11B1 | |
| SCHEMBL2793975 | 0.80 | CACNA2D1 (0.57) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL18390861 | 0.79 | MEN1 (0.69) | HSD11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | claimed |
| EP-2061780-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008031227-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-03-20 | — | — | WO | claimed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| WO-2008031227-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1B, ORAI1 | CACNA2D1 22/4885CACNA1B 2/4885CACNB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.